Pre-Fall 2026 Denim
Continue reading →
Sri Lanka’s Apparel Sector Celebrates Duty-Free Access to UK Market
In what could be viewed as a gift to usher in the new year, the wider tariff-free access announced last year by the United Kingdom came into effect earlier than expected. Continue reading →
4PL model reemerges as disruptive market dynamics buffet shippers
Technology analyst Gartner’s recent release of a report categorizing 4PL providers signals renewed interest in the concept, even as questions remain about which shippers it is best-suited for. Continue reading →
Cosco inks almost $2.7 billion in deals for 18 newbuild container ships
The agreements include the construction of a dozen 18,000-TEU, LNG-powered vessels that are part of the massive $7 billion fleet renewal program the carrier unveiled in early December. Continue reading →
Intermodal cooperation on rails has declined amid cost pressures
Cooperation in the form of steel-wheel interchange has fallen out of fashion as railroads have become less willing to do the necessary work that is intrinsic in the swap of volume on rail, according to Larry Gross. Continue reading →Patch Tuesday, January 2026 Edition
Microsoft today issued patches to plug at least 113 security holes in its various Windows operating systems and supported software. Eight of the vulnerabilities earned Microsoft’s most-dire “critical” rating, and the company warns that attackers are already exploiting one of...
Mobile homes already have huge utility bills. Congress may make it worse.
The U.S. House of Representatives approved a bill to transfer energy standards for manufactured homes from the Department of Energy to HUD. Continue reading →
Microsoft’s Brad Smith pushes Big Tech to ‘pay our way’ for AI data centers amid rising opposition
Microsoft’s president, Brad Smith, is meeting federal lawmakers to advocate for Big Tech to cover costs of AI data centers, amid local opposition. Continue reading →
When the placebo isn’t inert: Rezolute’s CEO on the 40% response rate that upended a phase 3 trial
As recently as December 10, 2025, Rezolute was a Wall Street darling. Eight analysts rated the stock a Buy, with price targets as high as $17. Its lead drug ersodetug, a monoclonal antibody, had earned two FDA Breakthrough Therapy Designations and the agency had signaled that its Phase 3 trial...